Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02988128 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurovascular Product Surveillance Registry

Study acronym: INSPIRE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 65 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 15 words
    • Site details revised at 7 of 99 sites
  2. Site details revised at 1 of 99 sitesv64
  3. Site details revised at 1 of 99 sitesv63
  4. Site details revised at 2 of 99 sitesv62
  5. Site details revised at 1 of 99 sitesv61
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 98 to 99v60
  2. Site details revised at 3 of 98 sitesv59
  3. Site details revised at 1 of 98 sitesv58
  4. Site details revised at 1 of 98 sitesv57
  5. Site details revised at 6 of 98 sitesv56
  6. Site details revised at 37 of 98 sitesv55
  7. Site details revised at 1 of 98 sitesv54
  8. Site details revised at 6 of 98 sitesv53
  9. Site details revised at 2 of 98 sitesv52
  10. Site details revised at 2 of 98 sitesv51
  11. Primary and study completion dates: Nov 2026 to Aug 2032v50 Show 5 more changesShow less
    • Enrollment target: 3000 to 4000
    • Eligibility criteria expanded, about 146 words
    • Site details revised at 1 of 98 sites
    • Study arms: 0 to 2
    • Study description expanded, about 1 word
  12. Site details revised at 1 of 98 sitesv49
  13. Site details revised at 14 of 98 sitesv48
  14. Study sites: 97 to 98v47
  15. Study sites: 95 to 97v46
  16. Study sites: 89 to 95v45
  17. Study sites: 84 to 89v44
  18. Study sites: 83 to 84v43
  19. Study sites: 82 to 83v42
  20. Study sites: 80 to 82v41
  21. Study sites: 79 to 80v40
  22. Study sites: 78 to 79v39
  23. Study sites: 74 to 78v38
  24. Study sites: 71 to 74v37
  25. Study sites: 66 to 71v36
  26. Study sites: 60 to 66v35
  27. Study sites: 59 to 60v34
  28. Site details revised at 2 of 59 sitesv33
  29. Study sites: 58 to 59v32
  30. Study sites: 57 to 58v31
  31. Study sites: 53 to 57v30
  32. Study sites: 52 to 53v29
  33. Study sites: 50 to 52v28
  34. Site details revised at 1 of 50 sitesv27
  35. Site details revised at 3 of 50 sitesv26
  36. Site details revised at 1 of 50 sitesv25
  37. Site details revised at 2 of 50 sitesv24
  38. Study sites: 47 to 50v23
  39. Re-verified, no change to tracked fieldsv22
  40. Site details revised at 2 of 47 sitesv21
  41. Study sites: 46 to 47v20
  42. Study sites: 44 to 46v19
  43. Primary completion date: Nov 2020 to Nov 2026
    • Study completion date: Nov 2023 to Nov 2026
    • Site details revised at 3 of 44 sites
    v18
  44. 2 versions Re-verified since Sep 16, 2020, no change to tracked fieldsv16-v17
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Post market surveillance registry
Trial Details
NCT Number NCT02988128
Lead Sponsor Medtronic Neurovascular Clinical Affairs
Collaborators: Medtronic Cardiac Rhythm and Heart Failure
Conditions
(from sponsor)		 Intracranial Aneurysm, Stroke, Ischemic
Related terms Intracranial Aneurysm, Ischemic Stroke
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov